This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Study Published In JAMA Shows Covidien Endoscopic Ablation Therapy Effective In Treating Barrett’s Esophagus

An innovative Covidien (NYSE: COV) technology is effective at treating Barrett’s esophagus (a precancerous condition of the esophagus), according to a clinical study published in The Journal of the American Medical Association (JAMA).

The March 25 JAMA publication announced results from the SURF Trial ( SUrveillance vs. Radio Frequency ablation). SURF was a multi-center, randomized, investigator-sponsored clinical trial that compared the Covidien Barrx™ RF Ablation System with endoscopic surveillance in patients with Barrett’s esophagus and a confirmed diagnosis of low-grade dysplasia. The study enrolled 136 patients at nine European sites between June 2007 and June 2011.

“In patients with Barrett’s esophagus containing confirmed low-grade dysplasia, endoscopic ablation significantly reduced disease progression to high-grade dysplasia and esophageal cancer as compared to surveillance alone,” said principal investigator Jacques Bergman, M.D., Ph.D., professor of Gastrointestinal Endoscopy, director of Endoscopy, Academic Medical Center, Amsterdam, The Netherlands. “The difference in the disease progression outcome between the two groups was so large, in fact, that the data safety monitoring board overseeing the trial recommended early stoppage of the trial and patients in the control group were then offered endoscopic ablation.”

Barrett’s esophagus develops as a result of chronic injury from gastroesophageal reflux disease (GERD). The normal esophageal lining is replaced with abnormal cells (known as Barrett’s tissue), putting patients at greater risk of developing cancer of the esophagus. Patients with Barrett’s who ultimately develop cancer typically do so through a series of steps, starting with early Barrett’s, then low-grade dysplasia or high-grade dysplasia and then cancer.

The SURF Trial was supported, in part, by a grant from Covidien GI Solutions and the Maag Lever Darm Stichting grant (WO 07-06) from the Dutch Digestive Diseases Foundation.

Covidien’s Barrx RF Ablation System is used as part of an endoscopic (non-surgical) procedure and uses radiofrequency energy to coagulate tissue and remove the Barrett’s epithelial tissue. In the United States, the Barrx system is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including but not limited to, the esophagus. Indications include Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett’s Esophagus, Dieulafoy Lesions, and Angiodysplasia.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs